

References

I-204

1. Lumoxiti (moxetumomab pasudotox-tdfk) injection, for intravenous use [package insert] AstraZeneca, Wilmington, DE. 04/2020.
2. Kreitman R, Dearden C, Zinzani P, et al. Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia. 2018; 32:1768–1777.
4. Kreitman R & Arons E. Update on Hairy Cell Leukemia. *Clin Adv Haematol Oncol.* 2018;16(3): 205-215.
5. NCCN: National Comprehensive Cancer Network (NCCN). Moxetumomab pasudotox-tdfk. NCCN Drugs and Biologics Compendium®. 2020.
6. Clinical PharmacologyTM Compendium. 2020. Tampa FL: Gold Standard, Inc. Moxetumomab pasudotox.
7. Micromedex DrugDex Compendium®. 2020. Moxetumomab pasudotox-tdfk (Lumoxiti)
8. Kreitman R, Pastan I. Contextualizing the use of moxetumomab pasudotox in the treatment of relapsed or refractory hairy cell leukemia. 2020; 25(1): e170–e177.
9. Kreitman RJ, Dearden CE, Zinzani PLL, et. al. Moxetumomab pasudotox-tdfk in heavily pretreated patients with relapsed/refractory hairy cell leukemia (HCL): Long-term follow up from the pivotal Phase 3 Trial. 2019: 134:2808.
10. Nobre, C.F., Newman, M.J., DeLisa, A. et al. Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: A review of clinical considerations. *Cancer Chemother Pharmacol* 2019: 84; 255–263.